NASDAQ$NVCT
Nuvectis Pharma Inc · Q2 2024 earnings
Q2 2024 earnings · · Before market open · Investor relations
Briefing
Nuvectis Pharma Inc reported its Q2 2024 financial results showing continued operating losses with no revenue generated.
The company incurred a net loss of $4.4 million for the three months ended June 30, 2024, driven by research and development expenses of $2.9 million and general and administrative expenses of $1.7 million. Cash and cash equivalents stood at $18.1 million, supporting operations for at least the next 12 months. The firm remains focused on advancing its clinical programs for NXP800 and NXP900 without any product revenue.
- No revenue was generated in Q2 2024 as the company remains in clinical development stage.
- Net loss narrowed to $4.4 million from $5.7 million in the prior year quarter due to reduced R&D spending.
- Cash position of $18.1 million provides runway for at least 12 months of operations.
- EPS improved to $(0.26) from $(0.38) year-over-year on higher share count.
Headline financials
Revenue & EPS history
Nuvectis Pharma · Revenue · Quarterly
$0
Forward guidance
The company expects to require additional capital to complete clinical trials and will continue to incur losses.
Tailwinds
- Cash runway of at least 12 months from existing resources
- Reduced quarterly net loss compared to prior year
Headwinds
- No revenue generation expected in near term
- Need to raise additional capital for ongoing development
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
+2.4%
Avg return
Earnings day
+7.2%
Avg return
5 days after
-3.7%
Avg return
30 days after
65%
13 / 20 earnings
Positive
+29.2%
Q3 2024
Best reaction
-14.9%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2024 | — | — | — | |
| Q1 2026 | +9.4% | +31.6% | +8.8% | |
| Q4 2026 | +0.5% | +0.2% | +3.3% | |
| Q3 2025 | -7.9% | -3.5% | +6.1% | |
| Q2 2025 | -5.4% | -17.7% | -10.6% | |
| Q1 2025 | +6.4% | +8.3% | -9.4% | |
| Q4 2024 | -5.8% | -9.1% | +31.1% | |
| Q3 2024 | +29.2% | +71.3% | -24.6% | |
| Q1 2024 | -14.9% | -15.3% | -13.6% | |
| Q4 2023 | -4.5% | -0.4% | -25.1% | |
| Q3 2023 | -7.9% | -6.6% | -8.4% | |
| Q2 2023 | +1.4% | +1.1% | -7.0% | |
| Q1 2023 | +5.8% | +6.3% | +14.0% | |
| Q4 2022 | -7.1% | -9.5% | +9.2% | |
| Q3 2022 | +0.9% | -3.5% | +7.7% | |
| Q3 2021 | +0.9% | -3.5% | +7.7% | |
| Q2 2021 | +1.1% | +10.1% | -0.6% | |
| Q2 2022 | +2.6% | -3.0% | -3.7% | |
| Q1 2021 | +18.8% | +28.8% | -24.4% | |
| Q4 2021 | +18.8% | +33.6% | -15.6% | |
| Q1 2022 | +5.4% | +25.2% | -19.4% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro